SAN DIEGO, May 12 /PRNewswire-FirstCall/ --
Protein Polymer Technologies, Inc. (OTC Bulletin Board: PPTI), today announced
that J. Thomas Parmeter, PPTI's President, will present a Company update at
the Techvest Annual European Conference on Global Opportunities in Biotech.
Mr. Parmeter's presentation will focus on the progress in the development and
testing of PPTI's injectable self-assembling silk-elastin hydrogel
formulations for the treatment of female stress urinary incontinence, and for
the treatment of dermal contour deficiencies (facial lines, wrinkles, and
scars).  Both of these products are in FDA-approved clinical trials.  He will
also comment on progress in the development of new applications based on the
Company's cross-linked adhesive hydrogels targeted on the repair of spinal
discs, and as tissue adhesives and sealants.
    The Techvest Conference, to be held May 19 and 20th in Amsterdam, has
become a premier event in the field of tissue repair and regeneration, with
presentations by more than 50 companies, as well as experts from the medical
and scientific community.  The forum provides an opportunity for U.S.
biotechnology companies to meet with representatives of the European financial
community and potential biomedical commercialization partners.  PPTI has
presented at four previous Techvest tissue engineering conferences in both the
U.S. and Europe.
    "The combination of population demographics and increased demand for
improving one's appearance are rapidly expanding the markets for treatment of
incontinence and for dermal contour corrections," said J. Thomas Parmeter,
President and Chief Executive Officer of Protein Polymer Technologies, Inc.
"Physicians continue to seek safe, effective, and more durable treatments in
response to patient demand.  These products are an ideal fit with our goal of
providing new classes of high performance biomaterials designed through
genetic and protein engineering to meet present and future needs in tissue
repair and regeneration."

    Protein Polymer Technologies, Inc., is a San Diego-based company focused
on developing bioactive products to improve medical and surgical outcomes.
From its inception in 1988, PPTI has been a pioneer in protein design and
synthesis, developing an extensive portfolio of proprietary biomaterials.
These genetically engineered biomaterials are high molecular weight proteins,
processed into products with physical and biological characteristics tailored
to specific clinical performance requirements.  Targeted products include
urethral bulking agents for the treatment of stress urinary incontinence,
dermal augmentation products for cosmetic and reconstructive surgery, surgical
adhesives and sealants, scaffolds for wound healing and tissue engineering,
and depots for local drug delivery.  To date, PPTI has been issued twenty-four
U.S. Patents on its core technology with corresponding issued and pending
patents in key international markets.

    This press release contains forward-looking statements that are based on
management's views and expectations.  Actual results could differ materially
from those expressed here; further, the Company is not obligated to comment
specifically on those differences.  Risks associated with the Company's
activities include scientific and product development uncertainties,
competitive products and approaches, continuing collaborative partnership
interest and funding, regulatory testing and approvals, and manufacturing
scale-up.  The reader is encouraged to refer to the Company's 2002 Annual
Report on Form 10-KSB, and other recent filings with the Securities and
Exchange Commission, copies of which are available from the Company, to
further ascertain the risks associated with the above statements.

Link to this page: